Genexine, Inc. and Binex Co. Ltd. have entered into partnership to jointly develop potential COVID-19 vaccine GX-19, in hopes of preventing yearly seasonal flus showing respiratory symptoms. GX-19 will be a DNA vaccine, developed using Genexine's platform technology and manufactured at Binex's facility. In an effort to expedite domestic research, Genexine had declared the formation of a consortium comprising itself, Binex, the International Vaccine Institute, GenNBio, kaist and postech for the development of GX-19.

Genexine and Binex will begin manufacturing clinical samples from March. The consortium expects to turn in a clinical test design to the drug ministry by June. This partnership enables Genexine and Binex to develop coronavirus vaccine.